Latest News Archive

Please select Category, Year, and then Month to display items

The first clinical PhD in nuclear medicine completed at the UFS

18 April 2024 | Story Andre Damons | Photo Charl Devenish

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans.

News Archive

Two scientists part of team that discovers the source of the highest energy cosmic rays at the centre of the Milky Way

2016-03-22

Artist's impression of the giant molecular clouds surrounding the Galactic Centre, bombarded by very high energy protons accelerated in the vicinity of the central black hole and subsequently shining in gamma rays.
Artist's impression: © Dr Mark A. Garlick/ H.E.S.S. Collaboration

Spotlight photo:
Dr Brian van Soelen and Prof Pieter Meintjes of the UFS Department of Physics.
Photo: Charl Devenish

H.E.S.S. (High Energy Stereoscopic System) scientists publically revealed their latest galactic discovery in the international science journal, Nature, on 16 March 2016. These scientists were able to pinpoint the most powerful source of cosmic radiation – which, up to now, remained a mystery.

Part of this team of scientists are Prof Pieter Meintjes and Dr Brian van Soelen, both in the University of the Free State (UFS) Department of Physics. Dr Van Soelen explains that they have discovered a proton PeVatron – a source that can accelerate protons up to energies of ~1 PeV (10^15 eV) – at the centre of the Milky Way. The supermassive black hole called Sagittarius A has been identified as the most plausible source of this unprecedented acceleration of protons.

The protons are accelerated to Very High Energy (VHE) gamma rays. The energy of these protons are 100 times larger than those achieved by the Large Hadron Collider at CERN (the European Organization for Nuclear Research).

According to Dr Van Soelen, the fact that this research has been published in Nature demonstrates the importance and pioneering nature of the research conducted by H.E.S.S. The H.E.S.S. observatory – operational in Namibia – is a collaboration between 42 scientific institutions in 12 countries.

In 2006, H.E.S.S. was awarded the Descartes Prize of the European Commission – the highest recognition for collaborative research – and in 2010 the prestigious Rossi Prize of the American Astronomical Society. The extent of the observatory’s significance places it among the ranks of the Hubble Space Telescope and the telescopes of the European Southern Observatory in Chile.

“The next generation VHE gamma-ray telescope,” Dr Van Soelen says, “will be the Cherenkov Telescope Array (CTA), which is currently in the design and development stage.” Both Dr Van Soelen and Prof Meintjes are part of this project as well.

H.E.S.S. has issued a complete statement about the paper published in Nature.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept